JP2020510816A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510816A5
JP2020510816A5 JP2019542716A JP2019542716A JP2020510816A5 JP 2020510816 A5 JP2020510816 A5 JP 2020510816A5 JP 2019542716 A JP2019542716 A JP 2019542716A JP 2019542716 A JP2019542716 A JP 2019542716A JP 2020510816 A5 JP2020510816 A5 JP 2020510816A5
Authority
JP
Japan
Prior art keywords
sftbp
cyfra21
pro
cea
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019542716A
Other languages
English (en)
Japanese (ja)
Other versions
JP7311417B2 (ja
JP2020510816A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/017704 external-priority patent/WO2018148600A1/en
Publication of JP2020510816A publication Critical patent/JP2020510816A/ja
Publication of JP2020510816A5 publication Critical patent/JP2020510816A5/ja
Application granted granted Critical
Publication of JP7311417B2 publication Critical patent/JP7311417B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019542716A 2017-02-09 2018-02-09 肺癌の検出および処置のための方法 Active JP7311417B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762456731P 2017-02-09 2017-02-09
US62/456,731 2017-02-09
PCT/US2018/017704 WO2018148600A1 (en) 2017-02-09 2018-02-09 Methods for the detection and treatment of lung cancer

Publications (3)

Publication Number Publication Date
JP2020510816A JP2020510816A (ja) 2020-04-09
JP2020510816A5 true JP2020510816A5 (enExample) 2021-03-25
JP7311417B2 JP7311417B2 (ja) 2023-07-19

Family

ID=63107741

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019542716A Active JP7311417B2 (ja) 2017-02-09 2018-02-09 肺癌の検出および処置のための方法

Country Status (8)

Country Link
US (3) US12504430B2 (enExample)
EP (2) EP3580560B1 (enExample)
JP (1) JP7311417B2 (enExample)
KR (2) KR102827354B1 (enExample)
CN (2) CN110291397A (enExample)
CA (1) CA3053116A1 (enExample)
ES (1) ES2995959T3 (enExample)
WO (1) WO2018148600A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108139381A (zh) 2015-06-26 2018-06-08 百奥马克癌症系统公司 肺癌检测方法
ES2995959T3 (en) 2017-02-09 2025-02-11 Univ Texas Methods for the detection and treatment of lung cancer
WO2021016711A1 (en) * 2019-07-29 2021-02-04 Biomark Cancer Systems Inc. Method of discriminating lung cancer patients
GB2603051B (en) 2020-01-30 2023-04-26 Prognomiq Inc Lung biomarkers and methods of use thereof
US20230213521A1 (en) * 2020-04-28 2023-07-06 Luxembourg Institute Of Health (Lih) Biomarkers for detection of lung cancer
EP4208712A4 (en) * 2020-09-01 2024-12-11 Oncodea Corporation PREDICTIVE DIAGNOSTIC TEST FOR EARLY DETECTION AND MONITORING OF DISEASE
CN112147099A (zh) * 2020-09-22 2020-12-29 范庆坤 一种m蛋白紫外分光检测法
KR20230080442A (ko) * 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료를 위한 방법
CN116529603A (zh) * 2020-10-02 2023-08-01 德州大学系统董事会 用于检测和治疗肺癌的方法
EP4237090B1 (en) * 2020-10-29 2026-02-18 Board of Regents, The University of Texas System Methods for the detection and treatment of ovarian cancer
JP2024505333A (ja) 2020-12-21 2024-02-06 フリーノム ホールディングス,インク. 結腸細胞増殖障害の早期検出のためのマーカー
AU2022249074A1 (en) 2021-03-31 2023-09-21 PrognomIQ, Inc. Multi-omic assessment
GB2607436A (en) * 2021-03-31 2022-12-07 Prognomiq Inc Multi-omic assessment
CN113267587B (zh) * 2021-05-27 2023-11-10 杭州广科安德生物科技有限公司 测定pro-SFTPB标准物质含量的特征肽段及方法
WO2023039479A1 (en) 2021-09-10 2023-03-16 PrognomIQ, Inc. Direct classification of raw biomolecule measurement data
JP2024534992A (ja) 2021-09-13 2024-09-26 プログノミック インコーポレイテッド 生体分子の増強された検出および定量
EP4515242A1 (en) * 2022-04-28 2025-03-05 JANSSEN Pharmaceutica NV Metabolite predictors for lung cancer
EP4357782A1 (en) * 2022-10-18 2024-04-24 MU Bioteknik Aktiebolag Protein biomarker panel for the diagnosis of colorectal cancer
CN115575636B (zh) * 2022-11-22 2023-04-04 杭州广科安德生物科技有限公司 一种用于肺癌检测的生物标志物及其系统
CN116593702B (zh) * 2023-05-11 2024-04-05 杭州广科安德生物科技有限公司 一种肺癌的生物标志物以及诊断系统
EP4781412A2 (en) * 2023-09-22 2026-07-29 Board of Regents, The University of Texas System Methods for the detection and treatment of lung cancer
CN118983078B (zh) * 2024-08-15 2025-03-25 立本医疗器械(成都)有限公司 基于ptr-tof-ms的肺癌筛查模型构建方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080133141A1 (en) 2005-12-22 2008-06-05 Frost Stephen J Weighted Scoring Methods and Use Thereof in Screening
EP3147665A1 (en) * 2005-12-22 2017-03-29 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
US9347945B2 (en) 2005-12-22 2016-05-24 Abbott Molecular Inc. Methods and marker combinations for screening for predisposition to lung cancer
WO2008144034A1 (en) 2007-05-18 2008-11-27 Duke University Serum biomarkers for the early detection of lung cancer
JP2013525814A (ja) 2010-05-07 2013-06-20 アッヴィ・インコーポレイテッド 標的化チロシンキナーゼインヒビターでの治療に対する感受性の予測方法
WO2011162904A2 (en) * 2010-05-24 2011-12-29 Marek Malecki Multidomain biotags for cancer detection, diagnosis and therapy and methods of their use priority statement
EP2577313A1 (en) 2010-06-03 2013-04-10 Porto Conte Ricerche S.r.l. Biomarkers for lung neuroendocrine tumors
JP5905003B2 (ja) 2010-07-09 2016-04-20 ソマロジック・インコーポレーテッド 肺癌バイオマーカーとその使用
CN102321760A (zh) 2011-08-26 2012-01-18 泸州医学院附属医院 一种非小细胞肺癌标志物及应用
CA2799163C (en) * 2011-12-18 2025-01-07 20/20 Genesystems, Inc. Methods and algorithms for aiding in the detection of cancer
WO2013154998A1 (en) 2012-04-09 2013-10-17 Duke University Serum biomarkers and pulmonary nodule size for the early detection of lung cancer
US20140271453A1 (en) 2013-03-14 2014-09-18 Abbott Laboratories Methods for the early detection of lung cancer
US9753037B2 (en) * 2013-03-15 2017-09-05 Rush University Medical Center Biomarker panel for detecting lung cancer
US20150072890A1 (en) 2013-09-11 2015-03-12 20/20 Gene Systems, Inc. Methods and compositions for aiding in the detection of lung cancer
US20160060329A1 (en) 2014-07-28 2016-03-03 Donald SIN Compositions and methods for the diagnosis and prognosis of lung cancer
CN108139381A (zh) 2015-06-26 2018-06-08 百奥马克癌症系统公司 肺癌检测方法
WO2017155570A1 (en) 2016-03-08 2017-09-14 Magarray, Inc. Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer
CN105717146B (zh) * 2016-03-29 2018-11-09 复旦大学附属中山医院 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒
CN109478231A (zh) 2016-04-01 2019-03-15 20/20基因系统股份有限公司 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物
EP3361256A1 (en) 2017-02-08 2018-08-15 Fundación para la Investigación Médica Aplicada In vitro method for the diagnosis of lung cancer
ES2995959T3 (en) 2017-02-09 2025-02-11 Univ Texas Methods for the detection and treatment of lung cancer
KR20250047324A (ko) 2017-08-07 2025-04-03 더 존스 홉킨스 유니버시티 암을 평가하고 치료하기 위한 방법 및 재료
KR20230080442A (ko) 2020-10-02 2023-06-07 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 폐암의 검출 및 치료를 위한 방법
WO2024107923A1 (en) 2022-11-17 2024-05-23 Board Of Regents, The University Of Texas System Methods for the detection and treatment of lung cancer
TR2022022101A2 (tr) 2022-12-31 2023-04-24 Atatuerk Ueniversitesi Fikri Muelkiyet Haklari Koordinatoerluegue Doener Sermaye Isletmesi Nemlendi̇ri̇ci̇ modelaj örtüsü
JP2026520689A (ja) 2023-05-31 2026-06-24 ボード オブ レジェンツ,ザ ユニバーシティ オブ テキサス システム 肺癌の検出及び治療方法
EP4781412A2 (en) 2023-09-22 2026-07-29 Board of Regents, The University of Texas System Methods for the detection and treatment of lung cancer

Similar Documents

Publication Publication Date Title
Wei et al. Plasma extracellular vesicles detected by Single Molecule array technology as a liquid biopsy for colorectal cancer
Zhao et al. Extracellular vesicles as cancer liquid biopsies: from discovery, validation, to clinical application
Fung et al. Classification of cancer types by measuring variants of host response proteins using SELDI serum assays
Jenkinson et al. Decreased serum thrombospondin-1 levels in pancreatic cancer patients up to 24 months prior to clinical diagnosis: association with diabetes mellitus
Wang et al. Investigation and identification of potential biomarkers in human saliva for the early diagnosis of oral squamous cell carcinoma
EP3623814A2 (en) Biomarker for monitoring or diagnosing onset of liver cancer in high-risk group for liver cancer and use thereof
JP2023545017A5 (enExample)
US8653006B2 (en) Metabolite biomarkers for the detection of esophageal cancer using NMR
JPWO2016163539A1 (ja) 肝疾患の病態を判別する方法
CN113791219B (zh) 用于急性缺血性脑卒中复发风险分析的生物标志物及其应用
JP7179356B2 (ja) 代謝物分析を利用したベーチェット病の診断方法
JP2020514689A5 (enExample)
Honda et al. Potential usefulness of apolipoprotein A2 isoforms for screening and risk stratification of pancreatic cancer
Sahni et al. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma
WO2019185692A1 (en) Metabolite-based breast cancer detection and diagnosis
CN106370744A (zh) 8‑羟基脱氧鸟苷作为尿液标志物的应用
Yi et al. Metabolomic identification of novel biomarkers of nasopharyngeal carcinoma
Kim et al. Differential levels of L‑homocysteic acid and lysophosphatidylcholine (16: 0) in sera of patients with ovarian cancer
Liang et al. Lipidomics analysis based on liquid chromatography mass spectrometry for hepatocellular carcinoma and intrahepatic cholangiocarcinoma
Choi et al. Evaluation of revisited fucosylated alpha-fetoprotein (AFP-L3) with an autoanalyzer μTAS in a clinical laboratory
Gîrleanu et al. Platelet indices in patients with de novo portal vein thrombosis and liver cirrhosis
Kohli et al. Surface-enhanced laser desorption/ionization time-of-flight mass spectrometry (SELDI-TOF MS) for determining prognosis in advanced stage hormone relapsing prostate cancer
KR20230113742A (ko) 난소암의 검출 및 치료를 위한 방법
CN118658612A (zh) 一种基于外泌体蛋白标志物的肺癌辅助诊断和预后评估的系统
Christensen et al. Practical approaches to proteomic biomarkers within prostate cancer radiotherapy trials